So, Novartis think that Alnylam's patents are worth $10 million, and the market thinks Alnylam are worth $10 billion.
Kind of proves that the foundation patents don't matter anymore.
- Forums
- ASX - By Stock
- Arrowhead buys Novartis' RNAi assets
So, Novartis think that Alnylam's patents are worth $10 million,...
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)